地塞米松联合尿激酶在早期粘连性结核性胸膜炎中的应用价值

目的探讨地塞米松联合尿激酶在早期粘连性结核性胸膜炎治疗中的价值。方法选取2012年1月至2013年1月莱芜市人民医院收治的80例早期粘连性结核性胸膜炎患者,采用简单随机化分组法将患者分为两组,各40例,均签署知情同意书。对照组采用常规治疗方法;治疗组在常规治疗基础上采用地塞米松联合尿激酶的治疗方法。观察两组患者胸腔积液消失时间、胸膜厚度、肺功能及安全性。结果治疗组胸腔积液消失时间短于对照组、胸膜厚度小于对照组、肺功能第一秒用力呼气量、用力肺活量等改善情况显著优于对照组(P<0.05);治疗期间两组均无显著不良反应。结论地塞米松联合尿激酶治疗早期粘连性结核性胸膜炎的临床疗效显著、安全性高,值得临床推广及应用。

Application Value of the Dexamethasone Combined with Urokinase in the Tuberculous Pleurisy in the Early Stage

Objective To investigate the effect of dexamethasone combined with urokinase in the treatment for early stage adhesive tuberculous pleurisy. Methods A total of 80 cases of early stage adhesive tuberculous pleurisy treated in Laiwu People＇s Hospital during Jan. 2012 and Jan. 2013 were included, and they were randomly divided into 2 groups,40 cases in each group, all of which signed ＂ informed consent＂. The control group was given conventional treatment;the treatment group was given dexamethasone combined with urokinase on the basis of conventional therapy, and the disappearing time of pleural effusion, pleural thickness, pulmonary function and safety of the two groups were observed. Results In the treatment group the hydrothorax disappearance time was shorter than the control group, pleural thickness was less than the control group, the lung function of FEV1%, FVC% were significantly higher than the control group（ P 〈 0.05 ）. There were no obvious adverse effects in either group during the treatment. Conclusion The curative effect of dexamethasone combined with urokinase in the treatment of early adhesive tuberculous pleurisy is significant with high safety, and is worthy of the clinical promotion and application.